CA2425688A1 - Extended release erythromycin derivatives - Google Patents
Extended release erythromycin derivatives Download PDFInfo
- Publication number
- CA2425688A1 CA2425688A1 CA002425688A CA2425688A CA2425688A1 CA 2425688 A1 CA2425688 A1 CA 2425688A1 CA 002425688 A CA002425688 A CA 002425688A CA 2425688 A CA2425688 A CA 2425688A CA 2425688 A1 CA2425688 A1 CA 2425688A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- long chain
- host
- treating
- bacterial infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 title claims abstract description 36
- 238000013265 extended release Methods 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 57
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
- 229930195733 hydrocarbon Natural products 0.000 claims abstract description 13
- 150000002430 hydrocarbons Chemical class 0.000 claims abstract description 13
- 150000001733 carboxylic acid esters Chemical class 0.000 claims abstract description 8
- 150000001735 carboxylic acids Chemical class 0.000 claims abstract description 8
- 150000001298 alcohols Chemical class 0.000 claims abstract description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 19
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 19
- 229920000642 polymer Polymers 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000004215 Carbon black (E152) Substances 0.000 claims description 9
- 239000006186 oral dosage form Substances 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims 1
- 239000002861 polymer material Substances 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 20
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical class CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 14
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 14
- 229960002626 clarithromycin Drugs 0.000 description 14
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 14
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 239000008101 lactose Substances 0.000 description 12
- 229960001375 lactose Drugs 0.000 description 12
- 235000019359 magnesium stearate Nutrition 0.000 description 10
- 239000008187 granular material Substances 0.000 description 9
- 229960000541 cetyl alcohol Drugs 0.000 description 7
- 239000012847 fine chemical Substances 0.000 description 6
- 229940075507 glyceryl monostearate Drugs 0.000 description 6
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 6
- 235000021355 Stearic acid Nutrition 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- QHZLMUACJMDIAE-UHFFFAOYSA-N 1-monopalmitoylglycerol Chemical class CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 4
- 239000005995 Aluminium silicate Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 235000012211 aluminium silicate Nutrition 0.000 description 4
- OEUVSBXAMBLPES-UHFFFAOYSA-L calcium stearoyl-2-lactylate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O.CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O OEUVSBXAMBLPES-UHFFFAOYSA-L 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- 229960003276 erythromycin Drugs 0.000 description 4
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- QHZLMUACJMDIAE-SFHVURJKSA-N 1-hexadecanoyl-sn-glycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)CO QHZLMUACJMDIAE-SFHVURJKSA-N 0.000 description 3
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 description 3
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 3
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 229940080352 sodium stearoyl lactylate Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- PBYKCYPLADSNDM-QXMHVHEDSA-N CCCCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO Chemical compound CCCCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO PBYKCYPLADSNDM-QXMHVHEDSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- GGJRAQULURVTAJ-UHFFFAOYSA-N glyceryl monolinolenate Natural products CCC=CCC=CCC=CCCCCCCCC(=O)OCC(O)CO GGJRAQULURVTAJ-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- UTOPWMOLSKOLTQ-UHFFFAOYSA-N octacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O UTOPWMOLSKOLTQ-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- GGJRAQULURVTAJ-PDBXOOCHSA-N rac-1-alpha-linolenoylglycerol Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(=O)OCC(O)CO GGJRAQULURVTAJ-PDBXOOCHSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- VHOCUJPBKOZGJD-UHFFFAOYSA-N triacontanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O VHOCUJPBKOZGJD-UHFFFAOYSA-N 0.000 description 2
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 229930006677 Erythromycin A Natural products 0.000 description 1
- 239000004144 Ethoxylated Mono- and Di-Glyceride Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000010957 calcium stearoyl-2-lactylate Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940099371 diacetylated monoglycerides Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- VUXNZDYAHSFXBM-UHFFFAOYSA-N docos-13-ynoic acid Chemical compound CCCCCCCCC#CCCCCCCCCCCCC(O)=O VUXNZDYAHSFXBM-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 235000019334 ethoxylated mono- and di- glycerides Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- LQJBNNIYVWPHFW-QXMHVHEDSA-N gadoleic acid Chemical compound CCCCCCCCCC\C=C/CCCCCCCC(O)=O LQJBNNIYVWPHFW-QXMHVHEDSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- VNLRTFSQCPNNIM-UHFFFAOYSA-N octadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCC VNLRTFSQCPNNIM-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229920000223 polyglycerol Chemical class 0.000 description 1
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- ABTZKZVAJTXGNN-UHFFFAOYSA-N stearyl heptanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCC ABTZKZVAJTXGNN-UHFFFAOYSA-N 0.000 description 1
- 229940098758 stearyl heptanoate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Communicable Diseases (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
An extended release pharmaceutical composition comprised of an erythromycin derivative and non-polymer material for providing for extended release, in particular, a member selected from the group consisting of clays, long chain hydrocarbons, long chain carboxylic acids, long chain carboxylic acid esters , long chain alcohols, and mixtures thereof, with said member being present in an amount to provide for extended release of the erythromycin derivative.</S DOAB>
Description
EXTENDED RELEASE ERYTHROMYCIN DERIVATIVES
The invention relates to a pharmaceutical composition of erythromycin derivatives with an extended release profile.
Erythromycin, as well as derivatives thereof, have been used as an antibacterial agent, and are generally provided as an immediate release composition.
U.S. Patent 6,010,718 discloses a pharmaceutical composition having extended release characteristics wherein erythromycin or a derivative thereof is employed in a pharmaceutical composition wherein the pharmaceutically acceptable carrier for the erythromycin or derivative thereof is a polymer, with such polymer generally being in an amount from about 5% to about 50% by weight of the composition.
In accordance with an aspect the present invention, there is provided a pharmaceutical composition for extended release of an erythromycin derivative wherein such erythromycin derivative is combined with a non-polymer hydrophobic material. Such material provides for extended release of the erythromycin derivative and is preferably at least one of a clay, a long chain hydrocarbon, a long chain alcohol, a long chain ester or a long chain acid.
More particularly, the extended release characteristics for the erythromycin derivative are provided by coating the erythromycin derivative with a clay, a long chain hydrocarbon, a long chain alcohol, a long chain ester, or a long chain acid.
A long chain hydrocarbon is a hydrocarbon that contains at least 12 carbon atoms, and in general, such a hydrocarbon contains from about 12 to 22 carbon atoms. The hydrocarbon may be branched or unbranched, or may be saturated or unsaturated, and; when unsaturated, may contain one or more double bonds.
A long chain carboxylic acid and/or long chain carboxylic acid ester and/or a long chain alcohol also preferably contains at least 12 carbon atoms, and more preferably, contains from 12 to 22 carbon atoms. In general, such hydrocarbons are aliphatic hydrocarbons, and may be saturated or unsaturated and may be branched or unbranched. If unsaturated, the hydrocarbon portion may contain one or more double bonds. In addition, such long chain alcohols, esters and acids may contain three carbon rings or hydroxyl groups.
Thus, for example, a long chain alcohol is represented by an aliphatic hydrocarbon alcohol that preferably contains at least 12 carbon atoms, and may contain one or more hydroxyl groups.
As representative examples of long chain carboxylic acids, there may be mentioned:
n-dodecanoic acid, a-tetradecanoic acid, a-hexadecanoic acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, montanic acid and melissic acid. Also useful are unsaturated monoolefinic straight chain monocarboxylic acids. Examples of these are oleic acid, gadoleic acid and erucic acid. Also useful are unsaturated (polyolefinic) straight chain monocarboxyilic acid.
Examples of these are linoleic acid, ricinoleic acid, linolenic acid, arachidonic acid and behenolic acid. Useful branched acids include, for example, diacetyl tartaric acid.
As representative examples of long chain carboxylic acid esters, there may be mentioned: glyceryl monostearates; glyceryl monopalmitates; mixtures of glyceryl monostearate and glyceryl monopalmitate (Myvaplex 600. Eastman Fine Chemical Company); glyceryl monolinoleate; glyceryl monooleate; mixtures of glyceryl monopalmitate, glyceryl monostearate, glyceryl monooleate and glyceryl monolinoleate (Myverol 18-92, Eastman Fine Chemical Company); glyceryl monolinolenate;
glyceryl monogadoleate; mixtures of glyceryl monopalmitate, glyceryl monostearate, glyceryl monooleate, glyceryl monolinoleate, glyceryl monolinolenate and glyceryl monogadoleate (Myverol 18-99, Eastman Fine Chemical Company); acetylated glycerides such as distilled acetylated monoglycerides (Myvacet S-07, 7-07 and 9-45, Eastman Fine Chemical Company); mixtures of propylene glycol monoesters, distilled monoglycerides, sodium stearoyl lactylate and silicon dioxide (Myvatex TL, Eastman Fine Chemical Company);
mixtures of propylene glycol monoesters, distilled monoglycerides, sodium stearoyl lactylate and silicon dioxide (Myvatex TL, Eastman Fine Chemical Company) d-alpha tocopherol polyethylene glycol 1000 succinate (Vitamin E TPGS, Eastman Chemical Company);
mixtures of mono- and di-glyceride esters such as Atmul (Humko Chemical Division of Witco Chemical); calcium stearoyl lactylate; ethoxylated mono- and di-glycerides; lactated mono- and di-glycerides; lactylate carboxylic acid ester of glycerol and propylene glycol;
lactylic esters of long chain carboxylic acids; polyglycerol esters of long chain carboxylic acids, propylene glycol mono- and di-esters of long chain carboxylic acids;
sodium stearoyl lactylate; sorbitan monostearate; sorbitan monooleate; other sorbitan esters of long chain carboxylic acids; stearyl heptanoate; cetyl esters of waxes; stearyl octanoate; Clo-C3o cholesterol/lavosterol esters; and sucrose long chain carboxylic acid esters.
As representative examples of clays, there may be mentioned: Kaolin, Bentonite, magnesium aluminum silicate, magnesium trisilicate, talc, or calcium silicate.
The erythromycin derivative is coated with a material as hereinabove described to provide for sustained release of the erythromycin derivative.
The extended released material, as hereinabove described, is generally employed in an amount of from about 1 % to about 60%, by weight of the composition, and preferably from about 5% to about 50% of the composition.
The composition may further include pharmaceutically acceptable excipients and/or fillers and extenders such as lactose, starches, dicalcium phosphate, calcium sulfate, calcium carbonate, glucose, sucrose, mannitol and silicic acid, lubricants such as talc, calcium stearate, magnesium stearate, etc.
The invention relates to a pharmaceutical composition of erythromycin derivatives with an extended release profile.
Erythromycin, as well as derivatives thereof, have been used as an antibacterial agent, and are generally provided as an immediate release composition.
U.S. Patent 6,010,718 discloses a pharmaceutical composition having extended release characteristics wherein erythromycin or a derivative thereof is employed in a pharmaceutical composition wherein the pharmaceutically acceptable carrier for the erythromycin or derivative thereof is a polymer, with such polymer generally being in an amount from about 5% to about 50% by weight of the composition.
In accordance with an aspect the present invention, there is provided a pharmaceutical composition for extended release of an erythromycin derivative wherein such erythromycin derivative is combined with a non-polymer hydrophobic material. Such material provides for extended release of the erythromycin derivative and is preferably at least one of a clay, a long chain hydrocarbon, a long chain alcohol, a long chain ester or a long chain acid.
More particularly, the extended release characteristics for the erythromycin derivative are provided by coating the erythromycin derivative with a clay, a long chain hydrocarbon, a long chain alcohol, a long chain ester, or a long chain acid.
A long chain hydrocarbon is a hydrocarbon that contains at least 12 carbon atoms, and in general, such a hydrocarbon contains from about 12 to 22 carbon atoms. The hydrocarbon may be branched or unbranched, or may be saturated or unsaturated, and; when unsaturated, may contain one or more double bonds.
A long chain carboxylic acid and/or long chain carboxylic acid ester and/or a long chain alcohol also preferably contains at least 12 carbon atoms, and more preferably, contains from 12 to 22 carbon atoms. In general, such hydrocarbons are aliphatic hydrocarbons, and may be saturated or unsaturated and may be branched or unbranched. If unsaturated, the hydrocarbon portion may contain one or more double bonds. In addition, such long chain alcohols, esters and acids may contain three carbon rings or hydroxyl groups.
Thus, for example, a long chain alcohol is represented by an aliphatic hydrocarbon alcohol that preferably contains at least 12 carbon atoms, and may contain one or more hydroxyl groups.
As representative examples of long chain carboxylic acids, there may be mentioned:
n-dodecanoic acid, a-tetradecanoic acid, a-hexadecanoic acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, montanic acid and melissic acid. Also useful are unsaturated monoolefinic straight chain monocarboxylic acids. Examples of these are oleic acid, gadoleic acid and erucic acid. Also useful are unsaturated (polyolefinic) straight chain monocarboxyilic acid.
Examples of these are linoleic acid, ricinoleic acid, linolenic acid, arachidonic acid and behenolic acid. Useful branched acids include, for example, diacetyl tartaric acid.
As representative examples of long chain carboxylic acid esters, there may be mentioned: glyceryl monostearates; glyceryl monopalmitates; mixtures of glyceryl monostearate and glyceryl monopalmitate (Myvaplex 600. Eastman Fine Chemical Company); glyceryl monolinoleate; glyceryl monooleate; mixtures of glyceryl monopalmitate, glyceryl monostearate, glyceryl monooleate and glyceryl monolinoleate (Myverol 18-92, Eastman Fine Chemical Company); glyceryl monolinolenate;
glyceryl monogadoleate; mixtures of glyceryl monopalmitate, glyceryl monostearate, glyceryl monooleate, glyceryl monolinoleate, glyceryl monolinolenate and glyceryl monogadoleate (Myverol 18-99, Eastman Fine Chemical Company); acetylated glycerides such as distilled acetylated monoglycerides (Myvacet S-07, 7-07 and 9-45, Eastman Fine Chemical Company); mixtures of propylene glycol monoesters, distilled monoglycerides, sodium stearoyl lactylate and silicon dioxide (Myvatex TL, Eastman Fine Chemical Company);
mixtures of propylene glycol monoesters, distilled monoglycerides, sodium stearoyl lactylate and silicon dioxide (Myvatex TL, Eastman Fine Chemical Company) d-alpha tocopherol polyethylene glycol 1000 succinate (Vitamin E TPGS, Eastman Chemical Company);
mixtures of mono- and di-glyceride esters such as Atmul (Humko Chemical Division of Witco Chemical); calcium stearoyl lactylate; ethoxylated mono- and di-glycerides; lactated mono- and di-glycerides; lactylate carboxylic acid ester of glycerol and propylene glycol;
lactylic esters of long chain carboxylic acids; polyglycerol esters of long chain carboxylic acids, propylene glycol mono- and di-esters of long chain carboxylic acids;
sodium stearoyl lactylate; sorbitan monostearate; sorbitan monooleate; other sorbitan esters of long chain carboxylic acids; stearyl heptanoate; cetyl esters of waxes; stearyl octanoate; Clo-C3o cholesterol/lavosterol esters; and sucrose long chain carboxylic acid esters.
As representative examples of clays, there may be mentioned: Kaolin, Bentonite, magnesium aluminum silicate, magnesium trisilicate, talc, or calcium silicate.
The erythromycin derivative is coated with a material as hereinabove described to provide for sustained release of the erythromycin derivative.
The extended released material, as hereinabove described, is generally employed in an amount of from about 1 % to about 60%, by weight of the composition, and preferably from about 5% to about 50% of the composition.
The composition may further include pharmaceutically acceptable excipients and/or fillers and extenders such as lactose, starches, dicalcium phosphate, calcium sulfate, calcium carbonate, glucose, sucrose, mannitol and silicic acid, lubricants such as talc, calcium stearate, magnesium stearate, etc.
In accordance with the present invention, unlike U.S. Patent 6,010,718, extended release properties are achieved without using a polymer to provide such properties.
Although extended release properties are achieved in accordance with the invention by using the extended release agents as hereinabove described, whereby it is not necessary to add a polymer to the composition, it is possible to include a polymer in the composition for other purposes.
In general, if a polymer is present in the composition, such polymer is present in an amount of less than 5% by weight, generally in an amount less than 2% by weight, and more preferably in an amount less than 1% by weight. In most cases, the composition is free of a polymer in that a polymer is not required to achieve extended release properties.
The composition is preferably used as an oral dosage form; for example, in the form of a tablet or capsule.
The oral dosage form of the present invention which provides for extended release of an erythromycin derivative may also be employed in a liquid oral dosage form, which may include an emulsion, a micro-emulsion, a suspension, syrup, etc.
In general, the pharmaceutical composition of the present invention includes an erythromycin derivative in an amount from about 45% to about 60% by weight, and preferably contains about 50% by weight of the erythromycin derivative. The erythromycin derivative is preferably 6-0-methoxy erythromycin A, known as Clarithromycin.
The composition of the invention is administered to a host in an amount effective to treat a bacterial infection. A daily dose of the composition of the invention is preferably delivered in a single dose and can range from about 500 mg to 1000 mg per day, with the pharmaceutical generally being administered for periods of from 5 to 14 days.
It has been found that it is possible to provide an extended release pharmaceutical composition of an erythromycin derivative, without use of a polymer to provide for extended release, and that such a pharmaceutical composition has properties similar to those of the extended release composition of U.S. 6,010,718.
Although extended release properties are achieved in accordance with the invention by using the extended release agents as hereinabove described, whereby it is not necessary to add a polymer to the composition, it is possible to include a polymer in the composition for other purposes.
In general, if a polymer is present in the composition, such polymer is present in an amount of less than 5% by weight, generally in an amount less than 2% by weight, and more preferably in an amount less than 1% by weight. In most cases, the composition is free of a polymer in that a polymer is not required to achieve extended release properties.
The composition is preferably used as an oral dosage form; for example, in the form of a tablet or capsule.
The oral dosage form of the present invention which provides for extended release of an erythromycin derivative may also be employed in a liquid oral dosage form, which may include an emulsion, a micro-emulsion, a suspension, syrup, etc.
In general, the pharmaceutical composition of the present invention includes an erythromycin derivative in an amount from about 45% to about 60% by weight, and preferably contains about 50% by weight of the erythromycin derivative. The erythromycin derivative is preferably 6-0-methoxy erythromycin A, known as Clarithromycin.
The composition of the invention is administered to a host in an amount effective to treat a bacterial infection. A daily dose of the composition of the invention is preferably delivered in a single dose and can range from about 500 mg to 1000 mg per day, with the pharmaceutical generally being administered for periods of from 5 to 14 days.
It has been found that it is possible to provide an extended release pharmaceutical composition of an erythromycin derivative, without use of a polymer to provide for extended release, and that such a pharmaceutical composition has properties similar to those of the extended release composition of U.S. 6,010,718.
Tn particular, a pharmaceutical composition in accordance with the invention, (similarly to the pharmaceutical composition of U.S. Patent 6,010,718) can induce a statistically significantly lower mean fluctuation index in the plasma than ari immediate release composition while maintaining a similar bio-availability, or providing for increased bio-availability.
The invention will be further described with respect to the following examples;
however, the scope of the invention is not to be limited thereby. Unless otherwise specified, all parts and percentages are by weight.
Ingredient Conc.
Example 1: Clarithromycin 50 Lactose 19 Glyceryl monostearate 30 Magnesium Stearate 1.0 Method A: Melt the glyceryl monostearate and add the clarithromycin. Let cool and then mill through a screen. Blend the mixture with the lactose in a tumble blender for about 20 minutes. Add magnesium stearate and blend for 5 minutes. Compress the blend using a rotary tablet press.
Method B: Granulate lactose, glyceryl monostearate and clarithromycin together using a high shear granulator. Stop granulating when the gylceryl monosterate has completely melted. Screen the granulate. Blend the granulate and magnesium stearate for 5 minutes in a tumble blender. Compress the blend using a rotary tablet press.
Example 2: Clarithromycin 50 Lactose 19 Magnesium Stearate 1 Method A: Melt the ATMUL 84S and add the clarithromycin. Let cool and then mill through a screen. Blend the mixture with the lactose in a tumble blender for about 20 S
minutes. Add magnesium stearate and blend for 5 minutes. Compress the blend using a rotary tablet press.
Example 3: Clarithromycin 50 Lactose 35 Cetyl alcohol 10 Stearic Acid 5 Method A: Granulate lactose, cetyl alcohol and clarithromycin together using a high shear granulator. Stop granulating when the cetyl alcohol has completely melted.
Screen the granulate. Blend the granulate and magnesium stearate for 5 minutes in a tumble blender.
Compress the blend using a rotary tablet press.
Method B: Dissolve the cetyl alcohol in ethanol (95%). Granulate the clarithromycin and lactose with the cetyl alcohol solution. Screen the granulate and then dry.
Blend the dried granulate and stearic acid in a tumble blend for 5 minutes. Compress the blend using a rotary tablet press.
Example 4: Clarithromycin 50 Lactose 34 Kaolin 15 Magnesium Stearate 1 Example 5: Clarithromycin 50 Lactose 30 Starch 3 Kaolin 16 Magnesium Stearate 1 Example 6: Clarithromycin 50 Lactose 25 Starch 3 Cetyl alcohol 17 Stearic Acid 5 Example 7: Clarithromycin 50 Sucrose 25 Starch 3 Cetyl alcohol 17 Stearic Acid 5 Example 8: Clarithromycin 50 Dextrose 34 Kaolin 15 Magnesium Stearate 1 The compositions of Examples 4-8 are formulated in a manner similar to the previous examples.
Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, Within the scope of the pending claims, the invention may be practiced otherwise then as particularly described.
The invention will be further described with respect to the following examples;
however, the scope of the invention is not to be limited thereby. Unless otherwise specified, all parts and percentages are by weight.
Ingredient Conc.
Example 1: Clarithromycin 50 Lactose 19 Glyceryl monostearate 30 Magnesium Stearate 1.0 Method A: Melt the glyceryl monostearate and add the clarithromycin. Let cool and then mill through a screen. Blend the mixture with the lactose in a tumble blender for about 20 minutes. Add magnesium stearate and blend for 5 minutes. Compress the blend using a rotary tablet press.
Method B: Granulate lactose, glyceryl monostearate and clarithromycin together using a high shear granulator. Stop granulating when the gylceryl monosterate has completely melted. Screen the granulate. Blend the granulate and magnesium stearate for 5 minutes in a tumble blender. Compress the blend using a rotary tablet press.
Example 2: Clarithromycin 50 Lactose 19 Magnesium Stearate 1 Method A: Melt the ATMUL 84S and add the clarithromycin. Let cool and then mill through a screen. Blend the mixture with the lactose in a tumble blender for about 20 S
minutes. Add magnesium stearate and blend for 5 minutes. Compress the blend using a rotary tablet press.
Example 3: Clarithromycin 50 Lactose 35 Cetyl alcohol 10 Stearic Acid 5 Method A: Granulate lactose, cetyl alcohol and clarithromycin together using a high shear granulator. Stop granulating when the cetyl alcohol has completely melted.
Screen the granulate. Blend the granulate and magnesium stearate for 5 minutes in a tumble blender.
Compress the blend using a rotary tablet press.
Method B: Dissolve the cetyl alcohol in ethanol (95%). Granulate the clarithromycin and lactose with the cetyl alcohol solution. Screen the granulate and then dry.
Blend the dried granulate and stearic acid in a tumble blend for 5 minutes. Compress the blend using a rotary tablet press.
Example 4: Clarithromycin 50 Lactose 34 Kaolin 15 Magnesium Stearate 1 Example 5: Clarithromycin 50 Lactose 30 Starch 3 Kaolin 16 Magnesium Stearate 1 Example 6: Clarithromycin 50 Lactose 25 Starch 3 Cetyl alcohol 17 Stearic Acid 5 Example 7: Clarithromycin 50 Sucrose 25 Starch 3 Cetyl alcohol 17 Stearic Acid 5 Example 8: Clarithromycin 50 Dextrose 34 Kaolin 15 Magnesium Stearate 1 The compositions of Examples 4-8 are formulated in a manner similar to the previous examples.
Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, Within the scope of the pending claims, the invention may be practiced otherwise then as particularly described.
Claims (29)
- Claim 1. A pharmaceutical composition for an extended release of a erythromycin derivative in the gastrointestinal environment, comprising:
an erythromycin derivative, and at least one member selected from the group consisting of long chain hydrocarbons, long chain carboxylic acids, long chain carboxylic esters and long chain alcohols, said at least one member being present in an amount effective to provide for extended release of the erythromycin derivative in the composition, said erythromycin derivative in said composition having an extended release profile. - Claim 2. The pharmaceutical composition of claim 1 wherein said pharmaceutical composition is an oral dosage form.
- Claim 3. The pharmaceutical composition of claim 2 wherein said composition contains less than 1% of polymer, by weight.
- Claim 4. The pharmaceutical composition of claim 3 wherein said at least one member is present in an amount of about 1% to about 60% by weight.
- Claim 5. The pharmaceutical composition of claim 3 wherein said at least one member is a long chain carboxylic acid ester.
- Claim 6. The pharmaceutical composition of claim 3 wherein said at least one member is a long chain alcohol.
- Claim 7. The pharmaceutical composition of claim 3 wherein said at least one member is a long chain hydrocarbon.
- Claim 8. The pharmaceutical composition of claim 3 wherein said composition contains less than 3% of polymer, by weight.
- Claim 9. The pharmaceutical composition of claim 3 wherein said composition contains less than 1% by weight of polymer.
- Claim 10. The pharmaceutical composition of claim 4 wherein the erythromycin derivative is 6-0-methoxyerythromycin A.
- Claim 11. The pharmaceutical composition of claim 3 wherein the erythromycin derivative is present in the composition in an amount of from about 45% to 60%
by weight. - Claim 12. The composition of claim 3 wherein said composition provides a dose of the erythromycin derivative of from about 500 milligrams to about 1,000 milligrams.
- Claim 13. A tablet, comprising:
an erythromycin derivative; and at least one member selected from the group consisting of long chain hydrocarbons, long chain carboxylic acids, and long chain alcohols, said at least one member being present in an amount to provide for extended release of the erythromycin derivative, said erythromycin derivative in said tablet having an extended release profile. - Claim 14. The tablet of claim 13 wherein said composition contains less than 3% of polymer, by weight.
- Claim 15. The tablet of claim 14 said at least one member is a long chain carboxylic acid ester.
- Claim 16. The tablet of claim 14 wherein said at least one member is a long chain alcohol.
- Claim 17. The tablet of claim 14 wherein said at least one member is a long chain hydrocarbon.
- Claim 18. The tablet of claim 13 wherein the erythromycin derivative is 6-0-methoxyerythromycin A.
- Claim 19. The tablet of claim 13 wherein the erythromycin derivative is present in the composition in an amount of from about 45% to 60% by weight.
- Claim 20. The tablet of claim 19 wherein said composition provides a dose of the erythromycin derivative of from about 500 milligrams to about 1,000 milligrams.
- Claim 21. A process for treating a host for a bacterial infection, comprising:
treating a host with the composition of claim 1 in an amount effective to treat a bacterial infection. - Claim 22. A process for treating a host for a bacterial infection, comprising:
treating a host with the composition of claim 2 in an amount effective to treat a bacterial infection. - Claim 23. A process for treating a host for a bacterial infection, comprising:
treating a host with the composition of claim 8 in an amount effective to treat a bacterial infection. - Claim 24. A process for treating a host for a bacterial infection, comprising:
treating a host with the composition of claim 13 in an amount effective to treat a bacterial infection. - Claim 25. A process for treating a host for a bacterial infection, comprising:
treating a host with the composition of claim 18 in an amount effective to treat a bacterial infection. - Claim 26. A process for treating a host for a bacterial infection, comprising:
treating a host with the composition of claim 15 in an amount effective to treat a bacterial infection. - Claim 27. A process for treating a host for a bacterial infection, comprising:
treating a host with the composition of claim 16 in an amount effective to treat a bacterial infection. - Claim 28. A process for treating a host for a bacterial infection, comprising:
treating a host with the composition of claim 17 in an amount effective to treat a bacterial infection. - Claim 29. A process for treating a host for a bacterial infection, comprising:
treating a host with the composition of claim 19 in an amount effective to treat a bacterial infection.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68998800A | 2000-10-13 | 2000-10-13 | |
| US09/689,988 | 2000-10-13 | ||
| PCT/US2001/032055 WO2002038577A2 (en) | 2000-10-13 | 2001-10-12 | Extended release erythromycin derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2425688A1 true CA2425688A1 (en) | 2002-05-16 |
Family
ID=24770642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002425688A Abandoned CA2425688A1 (en) | 2000-10-13 | 2001-10-12 | Extended release erythromycin derivatives |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1333807A4 (en) |
| JP (1) | JP2004528272A (en) |
| AU (1) | AU2002239232A1 (en) |
| CA (1) | CA2425688A1 (en) |
| MX (1) | MXPA03003146A (en) |
| WO (1) | WO2002038577A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
| US6565882B2 (en) | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
| US6541014B2 (en) | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
| US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
| WO2005016278A2 (en) | 2003-08-12 | 2005-02-24 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
| EP1811986B1 (en) * | 2004-11-04 | 2014-03-26 | XenoPort, Inc. | Gabapentin prodrug sustained release oral dosage forms |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3108046A (en) * | 1960-11-25 | 1963-10-22 | Smith Kline French Lab | Method of preparing high dosage sustained release tablet and product of this method |
| JPS49107855A (en) * | 1973-02-03 | 1974-10-14 | ||
| JP2528652B2 (en) * | 1987-03-30 | 1996-08-28 | エスエス製薬株式会社 | Long-acting cefradine formulation |
| US4808411A (en) * | 1987-06-05 | 1989-02-28 | Abbott Laboratories | Antibiotic-polymer compositions |
| WO1991019486A1 (en) * | 1990-06-14 | 1991-12-26 | Kalmo Enterprises, Inc. | Stable aqueous drug suspensions |
| JP3265680B2 (en) * | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | Oral pharmaceutical composition |
| JPH07267850A (en) * | 1994-03-28 | 1995-10-17 | Eisai Co Ltd | Medicine composition prevented in unpleasant taste and method for producing the same |
| CA2219991C (en) * | 1995-05-02 | 2007-10-30 | Taisho Pharmaceutical Co., Ltd. | Taste masking pharmaceutical composition for oral administration |
| US5858986A (en) * | 1996-07-29 | 1999-01-12 | Abbott Laboratories | Crystal form I of clarithromycin |
| US6010718A (en) * | 1997-04-11 | 2000-01-04 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
| US5780604A (en) * | 1997-09-26 | 1998-07-14 | Abbott Laboratories | 11,12-cyclic phosphite or phosphate derivatives of erythromycin and related macrolides |
| JP2000169364A (en) * | 1998-09-30 | 2000-06-20 | Taisho Pharmaceut Co Ltd | Oral formulation particles |
| AU3192700A (en) * | 1999-03-17 | 2000-10-04 | Daiichi Pharmaceutical Co., Ltd. | Medicinal compositions |
| SI20244A (en) * | 1999-05-19 | 2000-12-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Melt granulation |
-
2001
- 2001-10-12 CA CA002425688A patent/CA2425688A1/en not_active Abandoned
- 2001-10-12 AU AU2002239232A patent/AU2002239232A1/en not_active Abandoned
- 2001-10-12 JP JP2002541109A patent/JP2004528272A/en active Pending
- 2001-10-12 WO PCT/US2001/032055 patent/WO2002038577A2/en not_active Ceased
- 2001-10-12 EP EP01986972A patent/EP1333807A4/en not_active Withdrawn
- 2001-10-12 MX MXPA03003146A patent/MXPA03003146A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002038577A2 (en) | 2002-05-16 |
| AU2002239232A1 (en) | 2002-05-21 |
| EP1333807A4 (en) | 2005-06-29 |
| MXPA03003146A (en) | 2004-12-06 |
| EP1333807A2 (en) | 2003-08-13 |
| JP2004528272A (en) | 2004-09-16 |
| WO2002038577A3 (en) | 2002-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2348988C (en) | Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor | |
| US8633241B2 (en) | Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol | |
| US4743450A (en) | Stabilized compositions | |
| EP2041084B1 (en) | Co-crystals of pyrrolidinones | |
| EP2783688A1 (en) | Pharmaceutical tablets of crystalline type ii aripiprazole | |
| AU2000249434A1 (en) | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same | |
| JPWO2007072908A1 (en) | Method for producing drug-containing wax matrix particles, extruder used in the method, and sustained-release preparation containing cilostazol | |
| JP2004501121A (en) | Compound having stable pharmaceutical effect and pharmaceutical preparation containing the same | |
| CA2425688A1 (en) | Extended release erythromycin derivatives | |
| KR100988233B1 (en) | Pharmaceutical compositions and preparations of clopidogrel 1,5-naphthalene disulfonic acid salts or hydrates thereof | |
| CN107397732A (en) | The method for improving Ezetimibe piece dissolution rate | |
| CA2355239C (en) | Pharmaceutical formulations | |
| AU7863098A (en) | Pharmaceutical preparations of cilansetron stabilized against racemization | |
| EP1296672B1 (en) | Stable pharmaceutical product and formulation | |
| AU3940999A (en) | Novel formulation containing paroxetine | |
| MXPA98006166A (en) | Pharmaceutical preparations of cilansetron stabilized against the racemizac | |
| MXPA00011154A (en) | Novel formulation containing paroxetine | |
| HK1037128A (en) | Non-crystalline solid dispersant comprising cefuromixe axetil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |